Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 225Ac-ABD147 |
Synonyms | |
Therapy Description |
225Ac-ABD147 is a radioconjugate comprising the alpha-radiation emitting radionuclide actinium-225 linked to an antibody that targets DLL3, which delivers radiation to DLL3-expressing tumor cells, potentially inhibiting tumor growth (Cancer Res (2024) 84 (6_Supplement): 6028). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
225Ac-ABD147 | DLL3 Antibody 7 | 225Ac-ABD147 is a radioconjugate comprising the alpha-radiation emitting radionuclide actinium-225 linked to an antibody that targets DLL3, which delivers radiation to DLL3-expressing tumor cells, potentially inhibiting tumor growth (Cancer Res (2024) 84 (6_Supplement): 6028). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06736418 | Phase I | 225Ac-ABD147 | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients with SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | Recruiting | USA | 0 |